JPWO2020010155A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020010155A5
JPWO2020010155A5 JP2021522935A JP2021522935A JPWO2020010155A5 JP WO2020010155 A5 JPWO2020010155 A5 JP WO2020010155A5 JP 2021522935 A JP2021522935 A JP 2021522935A JP 2021522935 A JP2021522935 A JP 2021522935A JP WO2020010155 A5 JPWO2020010155 A5 JP WO2020010155A5
Authority
JP
Japan
Prior art keywords
alkyl
independently selected
substituted
group
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021522935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529834A5 (https=
JP7482122B2 (ja
JP2021529834A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040418 external-priority patent/WO2020010155A1/en
Publication of JP2021529834A publication Critical patent/JP2021529834A/ja
Publication of JP2021529834A5 publication Critical patent/JP2021529834A5/ja
Publication of JPWO2020010155A5 publication Critical patent/JPWO2020010155A5/ja
Priority to JP2024072451A priority Critical patent/JP2024102170A/ja
Application granted granted Critical
Publication of JP7482122B2 publication Critical patent/JP7482122B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021522935A 2018-07-03 2019-07-02 Sting活性に関連する状態を治療するための化合物および組成物 Active JP7482122B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024072451A JP2024102170A (ja) 2018-07-03 2024-04-26 Sting活性に関連する状態を治療するための化合物および組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862693878P 2018-07-03 2018-07-03
US62/693,878 2018-07-03
US201962861078P 2019-06-13 2019-06-13
US62/861,078 2019-06-13
PCT/US2019/040418 WO2020010155A1 (en) 2018-07-03 2019-07-02 Compounds and compositions for treating conditions associated with sting activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024072451A Division JP2024102170A (ja) 2018-07-03 2024-04-26 Sting活性に関連する状態を治療するための化合物および組成物

Publications (4)

Publication Number Publication Date
JP2021529834A JP2021529834A (ja) 2021-11-04
JP2021529834A5 JP2021529834A5 (https=) 2022-07-11
JPWO2020010155A5 true JPWO2020010155A5 (https=) 2022-07-11
JP7482122B2 JP7482122B2 (ja) 2024-05-13

Family

ID=67441663

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021522935A Active JP7482122B2 (ja) 2018-07-03 2019-07-02 Sting活性に関連する状態を治療するための化合物および組成物
JP2024072451A Pending JP2024102170A (ja) 2018-07-03 2024-04-26 Sting活性に関連する状態を治療するための化合物および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024072451A Pending JP2024102170A (ja) 2018-07-03 2024-04-26 Sting活性に関連する状態を治療するための化合物および組成物

Country Status (6)

Country Link
US (1) US20210236466A1 (https=)
EP (1) EP3818044A1 (https=)
JP (2) JP7482122B2 (https=)
CN (1) CN112823151B (https=)
MA (1) MA53096A (https=)
WO (1) WO2020010155A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112823036B (zh) 2018-07-03 2024-11-08 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
EP3883651A1 (en) * 2018-11-19 2021-09-29 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
MA54753A (fr) * 2019-01-17 2021-11-24 Ifm Due Inc Composés et compositions pour traiter des états pathologiques associés à une activité de sting
TW202043198A (zh) * 2019-01-17 2020-12-01 美商Ifm Due有限公司 用於治療與sting活性相關之病況的化合物及組合物
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
US20230092163A1 (en) * 2019-06-14 2023-03-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN114761804A (zh) 2019-06-21 2022-07-15 艾福姆德尤股份有限公司 治疗癌症的方法
WO2021206158A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 がん治療方法
KR20230014681A (ko) * 2020-04-10 2023-01-30 에이비 사이언스 코로나바이러스 질환 2019(covid-19)의 치료를 위한 마시티닙의 용도
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
WO2022140397A1 (en) 2020-12-22 2022-06-30 Ifm Due, Inc. Methods of treating cancer
EP4267128A1 (en) 2020-12-22 2023-11-01 IFM Due, Inc. Methods of treating cancer
EP4267129A1 (en) 2020-12-22 2023-11-01 IFM Due, Inc. Methods of treating cancer
US20240060982A1 (en) 2020-12-22 2024-02-22 Ifm Due, Inc. Methods of treating cancer
TW202235073A (zh) 2021-01-08 2022-09-16 美商Ifm Due有限公司 用於治療與sting活性相關的病狀之化合物及組合物
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
UY39892A (es) 2021-08-10 2023-03-31 Novartis Pharma Ag Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING
CN116789641A (zh) * 2022-03-17 2023-09-22 中国科学院上海药物研究所 二氢异喹啉类化合物及其医药用途
CN114712365B (zh) * 2022-06-07 2022-08-23 山东绿叶制药有限公司 Trk抑制剂在制备治疗迟发性运动障碍药物中的应用
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN115960047B (zh) * 2023-01-10 2025-04-15 中国药科大学 一种3-苯基-1h-吡唑类化合物及其用途
WO2025111251A1 (en) * 2023-11-20 2025-05-30 Exelixis, Inc. Compounds that inhibit polo-like kinase 4

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3563985A (en) * 1967-12-15 1971-02-16 Fmc Corp Process for preparing certain acylaminoisothiazoles
US4230713A (en) * 1979-01-19 1980-10-28 Ici Americas Inc. Heterocyclic tetrahydro-1-alkyl-4-oxo-1H-imidazol-2-ylidene urea and phenyl esters of tetrahydro-1-alkyl-4-oxo-1H-imidazol-2-ylidene carbamic acid compounds
DE3332270A1 (de) * 1983-09-07 1985-03-21 Bayer Ag, 5090 Leverkusen Herbizide mittel enthaltend metribuzin in kombination mit 1,4-disubstituierten pyrazol-derivaten
US5849769A (en) * 1994-08-24 1998-12-15 Medivir Ab N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection
AU7726898A (en) * 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
ID26328A (id) * 1997-12-22 2000-12-14 Bayer Ag Penghambat raf kinase menggunakan urea heterosiklik tersubstitusi aril dan heteroaril
PY0117895A (es) * 2000-07-31 2003-11-03 Pfizer Prod Inc Derivados de imidazol
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
JP5039268B2 (ja) * 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
DK1618092T3 (da) * 2003-05-01 2011-01-31 Bristol Myers Squibb Co Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
JP2005104968A (ja) * 2003-09-12 2005-04-21 Sumitomo Chemical Co Ltd フェニルピラゾール化合物及びその用途
US20050192314A1 (en) * 2003-11-13 2005-09-01 Ambit Biosciences Corporation Urea derivatives as C-kit modulators
US20100160324A1 (en) * 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
EP1801098A1 (en) * 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
WO2012075380A1 (en) 2010-12-03 2012-06-07 The Trustees Of The University Of Pennsylvania Tip60 inhibitors
US9169248B2 (en) * 2012-12-21 2015-10-27 Chemocentryx, Inc. Diazole amides
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
WO2015039334A1 (en) * 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
CN109394752A (zh) 2013-10-21 2019-03-01 德雷克塞尔大学 治疗慢性乙型肝炎病毒感染的sting激动剂的用途
CN103739550B (zh) * 2014-01-02 2016-06-01 中国药科大学 2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用
JP2019510802A (ja) * 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited タンパク質調節物質として有用な複素環アミド
CN106986860A (zh) * 2017-05-19 2017-07-28 南京大学 一类含酰胺键的吡唑类抗肿瘤化合物的设计、合成
CN107417478B (zh) * 2017-06-05 2020-05-05 南京师范大学 一种催化氧化羰基化合成不对称二取代脲的方法
JP2020524718A (ja) * 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドCuradev Pharma Limited ヒトstingの複素環式小分子調節因子
EP3790500B1 (en) * 2018-05-10 2022-07-06 Koninklijke Philips N.V. Methods and systems for adjusting behavior of oral care device based on status of oral cavity

Similar Documents

Publication Publication Date Title
JPWO2020010155A5 (https=)
JP2021529834A5 (https=)
JPWO2020010092A5 (https=)
JP6839772B2 (ja) 抗PD−1抗体との組み合わせのための抗Tim−3抗体
JP6839761B2 (ja) 抗PD−L1抗体との組み合わせのための抗Tim−3抗体
JP6779299B2 (ja) 抗pd−l1抗体およびその使用
US10973915B2 (en) Anti-PD-1 antibodies and uses thereof
JP7046973B2 (ja) 抗ox40抗体およびその使用
JP7438958B2 (ja) 新規な抗体分子、その調製方法及びその使用
CN118373912A (zh) IL2Rβ/共同γ链抗体
WO2014180577A1 (en) Bispecific constructs and their use in the treatment of various diseases
JPWO2020135201A5 (https=)
WO2019030377A1 (en) CD96 BINDING AGENTS AS IMMUNOMODULATORS
CN119136840A (zh) 喜树碱类衍生物及配体-药物偶联物
JP7822576B2 (ja) 抗cldn4-抗cd137二重特異性抗体
JP2023509442A (ja) Cd73阻害剤とa2a/a2bアデノシン受容体阻害剤の併用療法
JPWO2021138419A5 (https=)
JPWO2020106736A5 (https=)
JPWO2020150439A5 (https=)
JP2021516251A (ja) 抗pd−1抗体との組み合わせのための抗cd137抗体
EP4603512A1 (en) B7h3/pdl1 bispecific antibody, and pharmaceutical composition comprising same and use thereof
RU2022107092A (ru) Новые анти-cldn18.2 антитела
KR20260016927A (ko) 항체 및 이의 용도
HK40104280A (en) Anti-cldn4/anti-cd137 bispecific antibody
TW202446799A (zh) 抗體及其用途